Gynecologic Oncology

Article	Citations
Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019	116
Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology – A systematic review and meta-analysis.	91
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer	89
Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification	80
Stromal POSTN induced by TGF-β1 facilitates the migration and invasion of ovarian cancer	76
Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes	69
Clinical assays for assessment of homologous recombination DNA repair deficiency	68
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer	61
Uterine serous carcinoma	60
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer	58
Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment	57
Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study	56
Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity	56
Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes	56
Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): Analysis on 1054 adnexal masses	55
Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers	54
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial	52
FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival	52
Gynecologic cancer in pregnancy	51
Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial	49
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer	49
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations	48
Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial	48
Artificial intelligence-assisted cytology for detection of cervical intraepithelial neoplasia or invasive cancer: A multicenter, clinical-based, observational study	48
Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer	47

Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma	45
Should endometrial biopsy under direct hysteroscopic visualization using the grasp technique become the new gold standard for the preoperative evaluation of the patient with endometrial cancer?	45
Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study	45
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study	45
Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study	44
Harnessing natural killer cells for the treatment of ovarian cancer	44
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract	43
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial	43
Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis	43
Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study	42
Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss	42
The current landscape of molecular profiling in the treatment of epithelial ovarian cancer	41
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial	41
Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer	41
Immunotherapy for platinum-resistant ovarian cancer	39
Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma	39
Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer	39
When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic	39
Lymphovascular space invasion in endometrial carcinoma: A prognostic factor independent from molecular signature	38
Homologous recombination deficiency real-time clinical assays, ready or not?	38
Ten-year outcomes following laparoscopic and open abdominal radical hysterectomy for “low-risk” early-stage cervical cancer: A propensity-score based analysis	37
Natural language processing with machine learning to predict outcomes after ovarian cancer surgery	37
Non-coding RNAs related to angiogenesis in gynecological cancer	37
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis	36
Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study	36
Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990–2017	35
Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer	35
The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on respo	35
High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomes	34
Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals	34
Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma	34
Cancer patients affected by COVID-19: Experience from Milan, Lombardy	33
Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends	33
The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration	33
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review	33
Predictors of recurrence following laparoscopic radical hysterectomy for early-stage cervical cancer: A multi-institutional study	33
Naples prognostic score is an independent prognostic factor in patients with operable endometrial cancer: Results from a retrospective cohort study	32
GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function	32
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)	32
Sentinel node mapping vs. sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: Results from a multi-institutional study	32
Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study	31
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer	31
Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement	31
Outcomes and patient perspectives following implementation of tiered opioid prescription guidelines in gynecologic surgery	31
Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy	30
The feature of cervical microbiota associated with the progression of cervical cancer among reproductive females	30
Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors	30
Survival outcomes in endometrial cancer patients having lymphadenectomy, sentinel node mapping followed by lymphadectomy and sentinel node mapping alone: Long-term results of a propensity-matched anal	30
Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update	30
Preoperative frailty assessment in patients undergoing gynecologic oncology surgery: A systematic review	30

Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol	30
CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes	30
The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance	30
Ovarian cancer symptoms, routes to diagnosis and survival – Population cohort study in the ‘no screen’ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)	29
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian can	29
Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer	28
Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?	28
Are ethnic and racial minority women less likely to participate in clinical trials?	28
Ultrasound detection of endometrial cancer in women with postmenopausal bleeding: Systematic review and meta-analysis	28
[18F]FDG-PET or PET/CT in the evaluation of pelvic and para-aortic lymph nodes in patients with locally advanced cervical cancer: A systematic review of the literature	28
Rapid dissemination of practice-changing information: A longitudinal analysis of real-world rates of minimally invasive radical hysterectomy before and after presentation of the LACC trial	28
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer	28
A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanc	27
Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis	27
Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: International expert consensus recommendations	27
Comparison between robot-assisted radical hysterectomy and abdominal radical hysterectomy for cervical cancer: A multicentre retrospective study	27
Updates on conservative management of endometrial cancer in patients younger than 45 years	27
Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial	27
Near-infrared fluorescence imaging compared to standard sentinel lymph node detection with blue dye in patients with vulvar cancer – a randomized controlled trial	27
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial	27
Racial disparities in high-risk uterine cancer histologic subtypes: A United States Cancer Statistics study	26
Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification	26
The role of semiquantitative evaluation of lympho-vascular space invasion in early stage cervical cancer patients	26
Physical activity and exercise in women with ovarian cancer: A systematic review	26
Management and outcomes of primary vaginal Cancer	26
Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer	26
Prospective analysis of circulating metabolites and endometrial cancer risk	25
Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer	25
Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma	25
POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women	25
Adapting and avoiding coping strategies for women with ovarian cancer during the COVID-19 pandemic	25
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial	25
The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes	25
Racial and ethnic disparities in palliative care utilization among gynecological cancer patients	25
Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer	25
Adjusting to the new reality: Evaluation of early practice pattern adaptations to the COVID-19 pandemic	25
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, plac	25
Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?	25
Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: A systematic review	25
Impact of Obesity on Sentinel Lymph Node Mapping in Patients with apparent Early-Stage Endometrial Cancer: The ObeLyX study	24
Global distribution, risk factors, and recent trends for cervical cancer: A worldwide country-level analysis	24
Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients	24
Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer	24
Oncologic results of fertility sparing surgery of cervical cancer: An updated systematic review	24
Clear cell carcinoma of the endometrium	24
Contemporary management of ovarian germ cell tumors and remaining controversies	24
Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer	24
Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases	24
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies	24
Neuroendocrine tumors of the gynecologic tract update	24
Feasibility, acceptability and effects of multimodal pelvic floor physical therapy for gynecological cancer survivors suffering from painful sexual intercourse: A multicenter prospective interventiona	24
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab	23
A systematic review on the use of artificial intelligence in gynecologic imaging – Background, state of the art, and future directions	23
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer	23
Is routine omentectomy of grossly normal omentum helpful in surgery for ovarian cancer? A look at the tumor microenvironment and its clinical implications	23
Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy	23
A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary ini	23
Diagnostic value of frozen section examination of sentinel lymph nodes in early-stage cervical cancer at the time of ultrastaging	23
Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis	23
Trends in HPV-dependent and HPV-independent vulvar cancers: The changing face of vulvar squamous cell carcinoma	23
Differences in cervical cancer screening and follow-up for black and white women in the United States	23
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes	23
Adipocytokines and their relationship to endometrial cancer risk: A systematic review and meta-analysis	23
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis	23
Using machine learning to create prognostic systems for endometrial cancer	23
Wait-time for hysterectomy and survival of women with early-stage cervical cancer: A clinical implication during the coronavirus pandemic	23
Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis	23
Angiogenesis in endometrial carcinoma: Therapies and biomarkers, current options, and future perspectives	22
Risk of vulvar, vaginal and anal high-grade intraepithelial neoplasia and cancer according to cervical human papillomavirus (HPV) status: A population-based prospective cohort study	22
Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer	22
Clear cell endometrial carcinomas with mismatch repair deficiency have a favorable prognosis: A systematic review and meta-analysis	22
Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines	22
Clinical impact of low-volume lymph node metastases in early-stage cervical cancer: A comprehensive meta-analysis	22
The impact of marital status on stage at diagnosis and survival of female patients with breast and gynecologic cancers: A meta-analysis	22
Effect of frailty on postoperative readmissions and cost of care for ovarian cancer	22
Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States	22
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study	22
The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis	22
Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials	22
Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)	21

A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study	21
Rural disparities in surgical care from gynecologic oncologists among Midwestern ovarian cancer patients	21
Racial disparities in survival among women with endometrial cancer in an equal access system	21
Reproductive and obstetric outcomes after abdominal radical trachelectomy (ART) for patients with early-stage cervical cancers in Fudan, China	21
MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer	21
Prospective cohort study of metabolic syndrome and endometrial cancer survival	21
Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer	21
Clinical and imaging findings in cervical cancer and their impact on FIGO and TNM staging – An analysis from the EMBRACE study	21
Adherence to treatment guidelines as a major determinant of survival disparities between black and white patients with ovarian cancer	21
The added value of sentinel node mapping in endometrial cancer	21
Surgical training in gynecologic oncology: Past, present, future	21
Clinical significance of homologous recombination deficiency score testing in endometrial Cancer	21
Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma	21
Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: A systematic review	20
Simple conization and pelvic lymphadenectomy in early-stage cervical cancer: A retrospective analysis and review of the literature	20
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer	20
Frailty Index for prediction of surgical outcome in ovarian cancer: Results of a prospective study	20
Clinical needs for transgender men in the gynecologic oncology setting	20
Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification	20
Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation	20
A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology	20
Crowdsourcing to measure financial toxicity in gynecologic oncology	20
Decreasing utilization of minimally invasive hysterectomy for cervical cancer in the United States	20
The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix	20
Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies	20
Ultra-radical upfront surgery does not improve survival in women with advanced epithelial ovarian cancer; a natural experiment in a complete population	20
Laparo-assisted vaginal radical hysterectomy as a safe option for Minimal Invasive Surgery in early stage cervical cancer: A systematic review and meta-analysis	20
Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2–4 cm; emerging data and future perspectives	20
DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan	19
When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer	19
PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer	19
Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management	19
Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort	19
Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy	19
Cervical conization before primary radical hysterectomy has a protective effect on disease recurrence in early cervical cancer: A two-center matched cohort study according to surgical approach	19
The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers	19
Mitigation and management strategies for ocular events associated with tisotumab vedotin	19
The risk of developing squamous cell carcinoma in patients with anogenital lichen sclerosis: A systematic review	19
A population-based study of causes of death after endometrial cancer according to major risk factors	19
Promoting health equity in the era of COVID-19	19
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer	19
Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification	19
Cost-effectiveness analysis comparing “PARP inhibitors-for-all” to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer	19
Minority participation in phase 1 gynecologic oncology clinical trials: Three decades of inequity	19
Diagnostic value of indocyanine green fluorescence guided sentinel lymph node biopsy in vulvar cancer: A systematic review	19
Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database	19
Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer	19
Age-related distribution of uncommon HPV genotypes in cervical intraepithelial neoplasia grade 3	18
Incidence trends of vulvar squamous cell carcinoma in Italy from 1990 to 2015	18
ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer	18
Comprehensive analysis of patient outcome after local recurrence of locally advanced cervical cancer treated with concomitant chemoradiation and image-guided adaptive brachytherapy	18
Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.	18
Patterns of recurrence and survival in vulvar cancer: A nationwide population-based study	18
Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis	18
Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial	18
Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: Long-term outcomes of a randomised trial	18
Visceral obesity and muscle mass determined by CT scan and surgical outcome in patients with advanced ovarian cancer. A retrospective cohort study	18
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect	18
Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer	18
Incidence and risk factors for lower limb lymphedema associated with endometrial cancer: Results from a prospective, longitudinal cohort study.	18
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II	18
Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial	18
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer	18
Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience	18
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial	18
Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement	18
Genomic characterization of vulvar squamous cell carcinoma	18
Maintaining surgical care delivery during the COVID-19 pandemic: A comparative cohort study at a tertiary gynecological cancer centre	18
Is the risk of substantial LVSI in stage I endometrial cancer similar to PORTEC in the North American population? – A single-institution study	18
Using rADioMIcs and machine learning with ultrasonography for the differential diagnosis of myometRiAL tumors (the ADMIRAL pilot study). Radiomics and differential diagnosis of myometrial tumors	18
Knowledge of endometrial cancer risk factors in a general gynecologic population	17
Where you live matters: A National Cancer Database study of Medicaid expansion and endometrial cancer outcomes	17
Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy	17
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZ	17
Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancer	17
The impact of an enhanced recovery after minimally invasive surgery program on opioid use in gynecologic oncology patients undergoing hysterectomy	17
Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer	17
Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer	17
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial	17
Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations	17
Significance of the number of high-risk factors in patients with cervical cancer treated with radical hysterectomy and concurrent chemoradiotherapy	17
Insomnia and its association with quality of life in women with ovarian cancer	17
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer	17
Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer	17
Incidence of vulvar high-grade precancerous lesions and cancer in Denmark before and after introduction of HPV vaccination	17
Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach	17
Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study (LBA 4)	17
An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275	17
TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review	17
Virtual visits among gynecologic oncology patients during the COVID-19 pandemic are accessible across the social vulnerability spectrum	17
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer	17
Historical and projected hysterectomy rates in the USA: Implications for future observed cervical cancer rates and evaluating prevention interventions	16
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study	16
Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)	16
Gynecologic cancer incidence and mortality among American Indian/Alaska Native women in the Pacific Northwest, 1996–2016	16